DOI: 10.1111/ajd.14139 ISSN: 0004-8380
A real‐world Australian experience of upadacitinib for the treatment of severe atopic dermatitis
Vanessa Tran, Gayle Ross- Dermatology
Abstract
Upadacitinib is a selective Janus kinase‐1 (JAK‐1) inhibitor that has been shown in clinical trials to be effective for the treatment of moderate‐to‐severe atopic dermatitis (AD). This study aimed to evaluate the real‐world experience of patients with AD treated with upadacitinib in a single‐centre Australian cohort. Our study revealed a higher propensity for herpetic infections compared with previous randomised controlled trials (RCTs).